Results 141 to 150 of about 21,749 (235)

Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Cardiovascular disease arises from lifelong accumulation of traditional and emerging risk factors that converge on shared pathophysiological pathways, leading to diverse clinical outcomes, and can be mitigated through integrated screening, prevention, and precision therapies. ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity
Mowei Kong   +6 more
wiley   +1 more source

Aerobic exercise partially improves the skeletal muscle phenotype in a model of heart failure with preserved ejection fraction in male mice. [PDF]

open access: yesPhysiol Rep
Martínez Martínez C   +8 more
europepmc   +1 more source

The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Inflammation in cardiovascular disease is a dynamic and context‐dependent network rather than a secondary response to injury. Mitochondrial danger signaling links metabolic stress to immune activation through TLR priming, NLRP3 inflammasome amplification, cGAS–STING signaling, and immunometabolic gating, providing a basis for more precise therapeutic ...
Jiaxiang Rong   +8 more
wiley   +1 more source

Cardiometabolic HFpEF: NASH of the Heart

open access: yesCirculation, 2023
Capone, Federico   +2 more
openaire   +4 more sources

A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications

open access: yesObesity Science &Practice, Volume 12, Issue 4, August 2026.
ABSTRACT Objective This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA‐approved OMMs.
Ariana M. Chao   +5 more
wiley   +1 more source

Neurokinin‐1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 15, Page 4246-4266, August 2026.
Background and Purpose The pathogenesis of type 2 diabetes mellitus (T2DM)‐induced cardiomyopathy involves cardiac fibrosis that leads to diastolic dysfunction. We established that replacement of lost substance P (SP) that occurs in T2DM reduces cardiac fibrosis and decreases inflammation in T2DM mice and non‐human primates.
Alexander Widiapradja   +11 more
wiley   +1 more source

Severe obesity in human HFpEF alters contractile protein function and organization. [PDF]

open access: yesScience
Jani VP   +20 more
europepmc   +1 more source

Letter to the Editor: Methodological Concerns Regarding “BCR in Heart Failure: When the Abstract Outruns the Evidence”

open access: yes
Clinical Cardiology, Volume 49, Issue 8, August 2026.
Jobab Nadeem   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy